Page 1

D Abbott Abbott Reports Third - Quarter 2021 Results ; Achieves Strong Double - Digit Earnings Growth and Raises Guidance ● ● ABBOTT PARK , Ill . , Oct. 20 , 2021 - Abbott today announced financial results for the third quarter ended Sept. 30 , 2021 . ● ● News Release ● Third - quarter sales growth of 23.4 percent ; organic sales growth of 22.4 percent GAAP diluted EPS from continuing operations growth of 69.6 percent ; adjusted diluted EPS growth of 42.9 percent Global COVID - 19 testing - related sales were $ 1.9 billion in the third quarter Excluding COVID - 19 testing - related sales , third - quarter sales grew 11.7 percent on both a reported and organic basis compared to sales in 2019 Continues to strengthen portfolio with several new product approvals Third - quarter sales of $ 10.9 billion increased 23.4 percent on a reported basis and 22.4 percent on an organic basis , which excludes the impact of foreign exchange . Third - quarter GAAP diluted EPS was $ 1.17 and adjusted diluted EPS , which excludes specified items , was $ 1.40 , reflecting 42.9 percent growth versus the prior year . ¹ Abbott projects full - year 2021 diluted EPS from continuing operations on a GAAP basis of $ 3.55 to $ 3.65 and full - year adjusted diluted EPS from continuing operations of $ 5.00 to $ 5.10 , reflecting growth of 38.4 percent at the mid - point versus prior year.² In August , Abbott announced U.S. FDA approval of its Amplatzer® Amulet® device , which offers immediate closure of the left atrial appendage - an area in the heart where blood clots can form . In August , Abbott announced results of the company's GUIDE - HF clinical trial , which showed Abbott's Cardio MEMS® remote monitoring system can improve care for more patients living with heart failure . Abbott filed a Premarket Approval ( PMA ) supplement with the FDA for consideration of an expanded indication for Cardio MEMS . In September , Abbott announced U.S. FDA approval of its Portico® with FlexNav® transcatheter aortic valve replacement ( TAVR ) system to treat people with symptomatic , severe aortic stenosis who are at high or extreme risk for open - heart surgery . During the third quarter , Abbott acquired Walk Vascular , LLC , a commercial - stage medical device company with a minimally invasive thrombectomy system designed to remove peripheral blood clots . " We achieved another quarter of strong growth overall and across all four of our major business areas , " said Robert B. Ford , president and chief executive officer , Abbott . " We're particularly pleased with the continued advancements of our new product pipeline , including several recent launches in large , high - growth markets . " -more Page 1 of 19